Document:

Exhibit

EXHIBIT 10.2
***Text Omitted and Filed Separately
with the Securities and Exchange Commission.
Confidential Treatment Requested
Under 17 C.F.R. Sections 200.80(b)(4) 
and 240.24b-2.

AMENDMENT ONE TO THE THIRD AMENDMENT TO TRADEMARK LICENSE
AND SUPPLY AGREEMENT
This Amendment One dated September 12, 2016 (the “Effective Date”) to the Third Amendment dated March 17, 2016 (the “Amendment”) to the Trademark License and Supply Agreement (“Agreement”) dated May 28, 2014 (“Effective Date”) as amended July 28, 2014 and September 30, 2015 by and between Mission Pharmacal Company (“Mission”) and Retrophin, Inc. (together with its affiliates, “Retrophin”).
WHEREAS, Mission and Retrophin have mutually agreed to amend the Budget for the Development Project. The amendments section of this Amendment set forth below in Section 1.0 shall amend and restate and replace in its entirety Sections in the Agreement as of the Effective Date. The below noted sections shall be incorporated into the Agreement as binding Sections of the Agreement on the Parties.
NOW THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, it is agreed that the following Sections shall be added to the Agreement which shall be amended as follows:
		
	1.0
	Exhibit B.

Exhibit B attached hereto will replace Exhibit B to the Amendment.
2.0  Except as set forth above, the Agreement shall remain in full force and effect.
3.0 All noted Amendments to the Agreement, including this Amendment and the Agreement, constitutes the entire agreement of the parties hereto with respect to the topics addressed therein and supersedes any and all prior agreements, whether oral or in writing between the parties hereto with respect to subject matter hereof. This Amendment may not be amended, modified or supplemented except by written agreement of the parties hereto. This Amendment may be executed in one or more counterparts, each of which shall be deemed and original, but all of which together shall constitute one and the same instrument.
IN WITNESS HEREOF, the undersigned have executed this Amendment on the day and year first above written.
[SIGNATURE PAGE FOLLOWS]

	
					
	RETROPHIN, INC.
	 
	MISSION PHARMACEUTICAL COMPANY

	 
	 
	 
	 
	 

	 
	 
	 
	 
	 

	By:
	/s/ Stephen Aselage
	 
	By:
	/s/Thomas J. Dooley

	Name: Stephen Aselage
	 
	Name: Thomas J. Dooley

	Title: Chief Executive Officer
	 
	Title: Chief Financial Officer

1

 
Exhibit B - Budget and Anticipated Timeline
Total anticipated development costs for the development of [...***...].
	
						
	 
	[...***...] Budget
	[...***...] Budget
	[...***...] Budget
	[...***...] Budget
	[...***...] Total Budget

	Manufacturing
	 
	 
	 
	 
	 

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	Regulatory & Development Strategy
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	Regulatory Activities
	 
	 
	 
	 
	 

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	CMC Support
	 
	 
	 
	 
	 

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	Clinical Program
	 
	 
	 
	 
	 

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	Third Party Pass-Through Costs
	 
	 
	 
	 
	 

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	 
	 
	 
	 
	 
	 

	Subtotal
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	 
	 
	 
	 
	 
	 

	Contingency
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

	 
	 
	 
	 
	 
	 

	Total
	[...***...]
	[...***...]
	[...***...]
	[...***...]
	[...***...]

2

Anticipated development milestone timeline for the development of [...***...].
	
		
	Key Milestones
	Target Completion Date

	[...***...]
	[...***...]

	[...***...]
	[...***...]

	[...***...]
	[...***...]

	[...***...]
	[...***...]

	[...***...]
	[...***...]

	[...***...]
	[...***...]

	[...***...]
	[...***...]

3trgp-ex42_524.htm

Exhibit 4.2

 

 US 4288794

 
AMENDMENT NO. 1 TO
REGISTRATION RIGHTS AGREEMENT

among

TARGA RESOURCES CORP.

and

THE PURCHASERS PARTY HERETO

 

 

 

 

AMENDMENT NO. 1 TO
REGISTRATION RIGHTS AGREEMENT

This AMENDMENT NO. 1 (this “Amendment”) to that certain Registration Rights Agreement, dated as of March 16, 2016 (the “Agreement”), by and among TARGA RESOURCES CORP., a Delaware corporation (the “Company”), and the purchasers set forth therein (the “Purchasers”), is made as of September 13, 2016, by and among the Company and Stonepeak Target Holdings, LP and Stonepeak Target Upper Holdings LLC (collectively, the “Requisite Holders”). Capitalized terms used but not defined herein have the meanings given such terms in the Agreement.

WHEREAS, the Company and the Purchasers are parties to the Agreement, pursuant to which the Company agreed to give certain registration rights to the Purchasers, in accordance with the provisions of the Agreement, in connection with the purchase by the Purchasers of Series A and Series B Warrants (the “Warrants”), exercisable into common stock of the Company, par value $0.001 (the “Common Stock”).

WHEREAS, pursuant to Section 1.01 of the Agreement, the “Registrable Securities” are the Common Stock issuable upon exercise of the Warrants, all of which are subject to the rights provided in the Agreement until such time as such securities cease to be Registrable Securities pursuant to the terms of the Agreement.

WHEREAS, pursuant to Section 3.11 of the Agreement, the Agreement may be amended by the written consent of the Company and the Holders of a majority of the outstanding Registrable Securities or securities convertible into Registrable Securities, as applicable.

WHEREAS, the Requisite Holders constitute the Holders of a majority of the outstanding Registrable Securities or securities convertible into Registrable Securities.

WHEREAS, the Company and the Requisite Holders desire to amend the Agreement as set forth in this Amendment in order to cure a mistake in the terms of the Agreement.

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

1.The definition of “Purchased Preferred Stock Price” in Section 1.01 of the Agreement is hereby amended and restated in its entirety as follows:

““Purchased Preferred Stock Price” means $20.77.”

2.Reference is made to that certain Series A Preferred Stock Purchase Agreement dated as of February 18, 2016 (the “Purchase Agreement”) between the Company and Stonepeak Target Holdings, LP.  The Company acknowledges and agrees that, notwithstanding the last sentence of Section 4.07 of the Purchase Agreement to the contrary, the ability of Stonepeak and its Affiliates to exercise any Warrants they own is not limited to 8,000,000 Registrable Securities in any fiscal quarter.

 

 

 

3.Except as expressly amended hereby, the Agreement remains unmodified and in full force and effect as originally executed without waiver of any provision thereof. Whenever the Agreement is referred to in any agreement, document or other instrument, such reference will be to the Agreement as amended hereby. In the event of any conflict between the terms of this Amendment and the Agreement, the terms of this Amendment shall prevail.

4.This Amendment shall be binding upon the Company, each of the Purchasers and such Purchasers’ respective successors and permitted assigns. Except as expressly provided in this Amendment, this Amendment shall not be construed so as to confer any right or benefit upon any Person other than the parties to this Amendment and their respective successors and permitted assigns.

5.This Amendment, and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of or relate to this Amendment or the negotiation, execution or performance of this Amendment (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Amendment), will be construed in accordance with and governed by the laws of the State of Delaware without regard to principles of conflicts of laws which would result in the application of the law of any other jurisdiction.

6.This Amendment may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same agreement.

[Remainder of Page Left Intentionally Blank]

 

 

2

 

IN WITNESS WHEREOF, the parties hereto execute this Amendment, effective as of the date first above written.

TARGA RESOURCES CORP.

By:/s/ Matthew J. Meloy

Matthew J. Meloy

Executive Vice President and Chief Financial Officer

[Signature page to Amendment No. 1 to Registration Rights Agreement]

STONEPEAK TARGET HOLDINGS LP

 

	
 
	
By:
	
STONEPEAK ASSOCIATES II LLC, its general partner

 

	
 
	
By:
	
STONEPEAK GP HOLDINGS II LP, its sole member

 

	
 
	
By:
	
STONEPEAK GP INVESTORS II LLC, its general partner

 

	
 
	
By:
	
STONEPEAK GP INVESTORS MANAGER LLC, its managing member

 

 

 

	
 
	
By:
	
/s/ Michael Dorrell

Michael Dorrell

Managing Member

 

STONEPEAK TARGET UPPER HOLDINGS LLC

MANAGING MEMBER: STONEPEAK INFRASTRUCTURE FUND II (AIV II) LP

 

	
 
	
By:
	
STONEPEAK ASSOCIATES II LLC, its general partner

 

	
 
	
By:
	
STONEPEAK GP HOLDINGS II LP, its sole member

 

	
 
	
By:
	
STONEPEAK GP INVESTORS II LLC, its general partner

 

	
 
	
By:
	
STONEPEAK GP INVESTORS MANAGER LLC, its managing member

 

 

 

	
 
	
By:
	
/s/ Michael Dorrell

Michael Dorrell

Managing Member

 

[Signature page to Amendment No. 1 to Registration Rights Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]